-+ 0.00%
-+ 0.00%
-+ 0.00%

MWX205 injection, a subsidiary of Lepu Medical (300003.SZ), obtained a notice of approval for drug clinical trials

Zhitongcaijing·11/10/2026 13:17:13
Listen to the news

Zhitong Finance App News, Lepu Healthcare (300003.SZ) issued an announcement. The company learned today that the company's holding subsidiary Shanghai Minwei Biotechnology Co., Ltd. (“Shanghai Minwei Biotech”) has received the “Drug Clinical Trial Approval Notice” (Notice Number: 2026LP03439) approved and issued by the State Drug Administration, and the MWX205 injection clinical trial application declared by Shanghai Minwei Biology has been approved.

Study name: A phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of MWX205 injection in mixed dyslipidemia adult participants with mixed dyslipidemia.